Entrada Therapeutics reports clinical-stage biopharmaceutical developments tied to its intracellular genetic-medicine platform and Endosomal Escape Vehicle therapeutics. Company updates center on RNA-based and oligonucleotide programs for neuromuscular and inherited retinal diseases, including Duchenne muscular dystrophy programs for exon 44, 45, 50 and 51 skipping-amenable patients.
Recurring news includes clinical data and study progress for ELEVATE programs, updates on ENTR-601-44 and other DMD candidates, the partnered VX-670 program for myotonic dystrophy type 1, and pipeline expansion into ocular disease such as Usher syndrome. Financial results, cash runway commentary, investor conference participation and Nasdaq inducement equity grants also appear in company communications.
Entrada Therapeutics (Nasdaq: TRDA) granted an aggregate of 12,990 RSUs to two newly hired non-executive employees effective March 1, 2026, under the company’s 2025 Inducement Equity Plan.
Grants were approved by the Compensation Committee per Nasdaq Listing Rule 5635(c)(4). Vesting: 25% on the one-year anniversary, then 6.25% quarterly on March 1, June 1, September 1 and December 1 thereafter, subject to continuous service and award agreements.
Entrada Therapeutics (Nasdaq: TRDA) reported Q4 and full‑year 2025 results and clinical updates on Feb 26, 2026. Key points: an independent DMC recommended initiation of ELEVATE‑44‑201 Cohort 2 at 12 mg/kg, multiple clinical readouts expected through 2026, and ENTR‑801 was nominated for USH2A.
Cash, cash equivalents and marketable securities were $295.7 million as of Dec 31, 2025, with a stated runway into Q3 2027; full‑year net loss was $143.8 million.
Entrada Therapeutics (Nasdaq: TRDA) reported that an independent Data Monitoring Committee recommended initiating Cohort 2 at 12 mg/kg in the ELEVATE-44-201 Phase 1/2 study, up from 6 mg/kg in Cohort 1.
Cohort 1 participants have moved into the open-label Phase 2 portion. The company expects Cohort 1 data in Q2 2026, Cohort 2 data by year-end, and Cohort 3 (up to 18 mg/kg) to follow. In December 2025, the FDA granted Rare Pediatric Disease Designation to ENTR-601-44.
Entrada Therapeutics (Nasdaq: TRDA) will present at two investor conferences in February and March 2026. CEO Dipal Doshi will take part in fireside chats at the Guggenheim Emerging Outlook: Biotech Summit on Feb 11, 2026 at 4:00 p.m. ET and the TD Cowen Health Care Conference on Mar 3, 2026 at 2:30 p.m. ET.
Both presentations offer live webcasts and replays available on the company investor relations website for 90 days after each event.
Entrada Therapeutics (Nasdaq: TRDA) reported clinical and preclinical progress across its RNA-based neuromuscular and ocular programs and confirmed cash to fund operations into Q3 2027. Key near-term milestones include planned data readouts from the first cohorts of ELEVATE-44-201 in Q2 2026 and ELEVATE-45-201 in mid-2026, initiation of a Phase 1/2 MAD study of ENTR-601-50 by end-2026, and global regulatory submissions for ENTR-601-51 in 2026. Entrada also nominated ENTR-801 as its first ocular clinical candidate for Usher syndrome type 2A and expects a second ocular candidate in 2026. The company will present at the J.P. Morgan Healthcare Conference on Jan 14, 2026.
Entrada Therapeutics (Nasdaq: TRDA) will present at the 44th Annual J.P. Morgan Healthcare Conference. Dipal Doshi, CEO, will deliver the company presentation on Wednesday, January 14, 2026 at 3:45 PM PT (6:45 PM ET). A live webcast will be available on Entrada’s Investor Relations site and will be archived for 30 days after the event.
Entrada Therapeutics (Nasdaq: TRDA) granted an aggregate of 40,650 RSUs and options to purchase 38,850 shares to five newly hired non-executive employees under its 2025 Inducement Equity Plan, effective Dec 1, 2025. The options have an exercise price of $9.91, equal to the closing price on Dec 1, 2025. Grants were approved by the Compensation Committee as inducements under Nasdaq Listing Rule 5635(c)(4).
Vesting: options vest 25% at one year then monthly over three years to full vest at four years; RSUs vest 25% at one year then 6.25% quarterly on Mar 1/Jun 1/Sep 1/Dec 1, subject to continued service. Grants are subject to the Inducement Plan and award agreements.
Entrada Therapeutics (Nasdaq: TRDA) reported Q3 2025 results and pipeline updates on Nov 6, 2025. The company reported $326.8M in cash, cash equivalents and marketable securities as of Sept 30, 2025 and expects runway into Q3 2027. Entrada is advancing multiple Duchenne muscular dystrophy programs: ELEVATE-44-201 (data from Cohort 1 expected Q2 2026), ELEVATE-45-201 (first patient dosed; Cohort 1 data mid-2026), and a regulatory filing in the U.K. to start ELEVATE-50-201 with EU filings planned H2 2026.
Q3 financials: collaboration revenue $1.6M, R&D expense $38.4M, G&A $10.3M, and net loss $(44.1)M.
Entrada Therapeutics (Nasdaq: TRDA) will present at two investor conferences in late 2025. The company said CEO Dipal Doshi will deliver a presentation at the Jefferies Global Healthcare Conference in London on November 18, 2025 at 5:00 p.m. GMT and will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Miami on December 3, 2025 at 12:55 p.m. ET.
Both events will be webcast live via the company’s Investor Relations website at www.entradatx.com, with replays available for 90 days after each event.
Entrada Therapeutics (Nasdaq: TRDA) has announced the recipients of its third annual DREAMS Grant Program, awarding $50,000 each to two non-profit organizations: Jett Foundation (US) and Parent Project aps (Italy). The grants aim to support underrepresented and underserved members of the Duchenne muscular dystrophy community.
Jett Foundation will utilize the funding for its Camp Promise program, targeting individuals aged 18 and older with Duchenne and other neuromuscular disorders, aiming to support over 250 campers in 2025. Parent Project aps will focus on providing home-based care and teleconsultation services to families in underserved regions of Southern Italy.
The recipients were selected by an independent grant review committee comprising neuromuscular leaders and advocates, with the announcement made ahead of World Duchenne Awareness Day on September 7.